Brenda M. Hofer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Brenda M. Hofer has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Inbeh Chung
Department of Urology, Stanford University School of Medicine, Stanford, California
6 shared publications - Daphne Y. Lichtensztajn
Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA
6 shared publications - Iona Cheng
Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, USA
6 shared publications - James D. Brooks
Department of Urology, Stanford University School of Medicine, Stanford, CA, USA
6 shared publications - John T. Leppert
Department of Urology, Stanford University School of Medicine, Stanford, California, USA
6 shared publications - Mindy C. DeRouen
Department of Epidemiology and Biostatistics, University of California, San Francisco, USA
6 shared publications
Latest Publications
- 12 March 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 71 (2) , 108333
Quality of Cancer Care in California After Full Implementation of the Affordable Care Act: Findings From a Population-Based Study
- 12 March 2026
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 71 (2) , 108333
Quality of Cancer Care in California After Full Implementation of the Affordable Care Act: Findings From a Population-Based Study
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population
Supplementary Table S2 shows the associations of comorbidity with RCC subtype stratified by race and ethnicity and by sex
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population
Supplementary Table S2 shows the associations of comorbidity with RCC subtype stratified by race and ethnicity and by sex
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population
Supplementary Table S4 shows the results of sensitivity analyses using different comorbidity definitions
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population
Supplementary Table S4 shows the results of sensitivity analyses using different comorbidity definitions
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population
Supplementary Table S1 lists the ICD-9 and ICD-10 codes used to define comorbidities
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population
Supplementary Table S1 lists the ICD-9 and ICD-10 codes used to define comorbidities
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population
Background:Renal cell carcinoma (RCC) subtypes differ in molecular characteristics and prognosis. We investigated the associations of RCC subtype with patient demographics, comorbidity, and neighborhood socioeconomic status (nSES).Methods:Using linked California Cancer Registry and Office of Statewide Health Planning and Development data, we identified history of hypertension, diabetes, and kidney disease prior to RCC diagnosis in Asian/Pacific Islander, non-Latino Black, Latino, and non-Latino White adults diagnosed with their first pathologically confirmed RCC from 2005 through 2015. We used multinomial multivariable logistic regression to model the association of demographics, comorbidity, and nSES with clear-cell, papillary, and chromophobe RCC subtype.Results:Of the 40,016 RCC cases included, 62.6% were clear cell, 10.9% papillary, and 5.9% chromophobe. The distribution of subtypes differed strikingly by race and ethnicity, ranging from 40.4% clear cell and 30.4% papillary in non-Latino Black adults to 70.7% clear cell and 4.5% papillary in Latino adults. In multivariable analysis, non-Latino Black individuals had a higher likelihood of presenting with papillary (OR, 3.99; 95% confidence interval, 3.61–4.42) and chromophobe (OR, 1.81; 1.54–2.13) versus clear-cell subtype compared with non-Latino White individuals. Both hypertension (OR, 1.19; 1.10–1.29) and kidney disease (OR, 2.38; 2.04–2.77 end-stage disease; OR, 1.52; 1.33–1.72 non–end-stage disease) were associated with papillary subtype. Diabetes was inversely associated with both papillary (OR, 0.63; 0.58–0.69) and chromophobe (OR, 0.61; 0.54–0.70) subtypes.Conclusions:RCC subtype is independently associated with patient demographics, and comorbidity.Impact:Targeted RCC treatments or RCC prevention efforts may have differential impact across population subgroups.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population
Background:Renal cell carcinoma (RCC) subtypes differ in molecular characteristics and prognosis. We investigated the associations of RCC subtype with patient demographics, comorbidity, and neighborhood socioeconomic status (nSES).Methods:Using linked California Cancer Registry and Office of Statewide Health Planning and Development data, we identified history of hypertension, diabetes, and kidney disease prior to RCC diagnosis in Asian/Pacific Islander, non-Latino Black, Latino, and non-Latino White adults diagnosed with their first pathologically confirmed RCC from 2005 through 2015. We used multinomial multivariable logistic regression to model the association of demographics, comorbidity, and nSES with clear-cell, papillary, and chromophobe RCC subtype.Results:Of the 40,016 RCC cases included, 62.6% were clear cell, 10.9% papillary, and 5.9% chromophobe. The distribution of subtypes differed strikingly by race and ethnicity, ranging from 40.4% clear cell and 30.4% papillary in non-Latino Black adults to 70.7% clear cell and 4.5% papillary in Latino adults. In multivariable analysis, non-Latino Black individuals had a higher likelihood of presenting with papillary (OR, 3.99; 95% confidence interval, 3.61–4.42) and chromophobe (OR, 1.81; 1.54–2.13) versus clear-cell subtype compared with non-Latino White individuals. Both hypertension (OR, 1.19; 1.10–1.29) and kidney disease (OR, 2.38; 2.04–2.77 end-stage disease; OR, 1.52; 1.33–1.72 non–end-stage disease) were associated with papillary subtype. Diabetes was inversely associated with both papillary (OR, 0.63; 0.58–0.69) and chromophobe (OR, 0.61; 0.54–0.70) subtypes.Conclusions:RCC subtype is independently associated with patient demographics, and comorbidity.Impact:Targeted RCC treatments or RCC prevention efforts may have differential impact across population subgroups.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population
Supplementary Table 3 shows the agreement between coded histology in registry data and electronic pathology reports
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population
Supplementary Table 3 shows the agreement between coded histology in registry data and electronic pathology reports
- 7 December 2022
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 32 (2) , 202-207
Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population
Background: Renal cell carcinoma (RCC) subtypes differ in molecular characteristics and prognosis. We investigated the associations of RCC subtype with patient demographics, comorbidity, and neighborhood socioeconomic status (nSES). Methods: Using linked California Cancer Registry and Office of Statewide Health Planning and Development data, we identified history of hypertension, diabetes, and kidney disease prior to RCC diagnosis in Asian/Pacific Islander, non-Latino Black, Latino, and non-Latino White adults diagnosed with their first pathologically confirmed RCC from 2005 through 2015. We used multinomial multivariable logistic regression to model the association of demographics, comorbidity, and nSES with clear-cell, papillary, and chromophobe RCC subtype. Results: Of the 40,016 RCC cases included, 62.6% were clear cell, 10.9% papillary, and 5.9% chromophobe. The distribution of subtypes differed strikingly by race and ethnicity, ranging from 40.4% clear cell and 30.4% papillary in non-Latino Black adults to 70.7% clear cell and 4.5% papillary in Latino adults. In multivariable analysis, non-Latino Black individuals had a higher likelihood of presenting with papillary (OR, 3.99; 95% confidence interval, 3.61–4.42) and chromophobe (OR, 1.81; 1.54–2.13) versus clear-cell subtype compared with non-Latino White individuals. Both hypertension (OR, 1.19; 1.10–1.29) and kidney disease (OR, 2.38; 2.04–2.77 end-stage disease; OR, 1.52; 1.33–1.72 non–end-stage disease) were associated with papillary subtype. Diabetes was inversely associated with both papillary (OR, 0.63; 0.58–0.69) and chromophobe (OR, 0.61; 0.54–0.70) subtypes. Conclusions: RCC subtype is independently associated with patient demographics, and comorbidity. Impact: Targeted RCC treatments or RCC prevention efforts may have differential impact across population subgroups.
- 7 December 2022
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 32 (2) , 202-207
Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population
Background: Renal cell carcinoma (RCC) subtypes differ in molecular characteristics and prognosis. We investigated the associations of RCC subtype with patient demographics, comorbidity, and neighborhood socioeconomic status (nSES). Methods: Using linked California Cancer Registry and Office of Statewide Health Planning and Development data, we identified history of hypertension, diabetes, and kidney disease prior to RCC diagnosis in Asian/Pacific Islander, non-Latino Black, Latino, and non-Latino White adults diagnosed with their first pathologically confirmed RCC from 2005 through 2015. We used multinomial multivariable logistic regression to model the association of demographics, comorbidity, and nSES with clear-cell, papillary, and chromophobe RCC subtype. Results: Of the 40,016 RCC cases included, 62.6% were clear cell, 10.9% papillary, and 5.9% chromophobe. The distribution of subtypes differed strikingly by race and ethnicity, ranging from 40.4% clear cell and 30.4% papillary in non-Latino Black adults to 70.7% clear cell and 4.5% papillary in Latino adults. In multivariable analysis, non-Latino Black individuals had a higher likelihood of presenting with papillary (OR, 3.99; 95% confidence interval, 3.61–4.42) and chromophobe (OR, 1.81; 1.54–2.13) versus clear-cell subtype compared with non-Latino White individuals. Both hypertension (OR, 1.19; 1.10–1.29) and kidney disease (OR, 2.38; 2.04–2.77 end-stage disease; OR, 1.52; 1.33–1.72 non–end-stage disease) were associated with papillary subtype. Diabetes was inversely associated with both papillary (OR, 0.63; 0.58–0.69) and chromophobe (OR, 0.61; 0.54–0.70) subtypes. Conclusions: RCC subtype is independently associated with patient demographics, and comorbidity. Impact: Targeted RCC treatments or RCC prevention efforts may have differential impact across population subgroups.
- Open Access
Childhood leukemia incidence in California: High and rising in the Hispanic population
BACKGROUND: High rates of childhood leukemia incidence have been reported in Latin America and among Hispanic children in the United States. California's large Hispanic population affords an important opportunity to perform a detailed analysis of the leukemia burden among Hispanic children.METHODS: Leukemias diagnosed among non‐Hispanic white (NHW), Hispanic, African American (AA), and Asian/Pacific Islander (API) children aged birth to 19 years between January 1, 1990 and December 31, 2012 were obtained from the California Cancer Registry (11,084 cases). Age‐adjusted incidence rates, standardized rate ratios (SRRs), and secular trends in incidence (annual percent change [APC]) were analyzed by subtype, race/ethnicity, sex, and age.RESULTS: Compared with NHW children, the incidence of acute lymphoblastic leukemia (ALL) was higher among Hispanic (SRR, 1.32) and lower among AA (SRR, 0.55) and API (SRR, 0.91) children. From 1990 to 2012, the incidence of ALL increased overall (APC, 1.1%) and among males (APC, 1.0%), females (APC, 1.3%), Hispanics (APC, 1.1%), AAs (APC, 1.9%), AA males (APC, 2.8%), API males (APC, 1.9%), and Hispanic females (APC, 1.5%). The incidence of ALL increased among Hispanic males aged 15 to 19 years (APC, 2.5%) and Hispanic females aged birth to 4 years and 15 to 19 years (APCs of 2.2% and 1.9%, respectively). The incidence of acute myeloid leukemia did not appear to differ among racial/ethnic groups. From 1990 to 2012, the overall incidence of acute myeloid leukemia remained stable but increased among Hispanics (APC, 1.2%), females (APC, 1.0%), Hispanic females (APC, 2.3%), and Hispanic females aged 15 to 19 years (APC, 3.4%).CONCLUSIONS: Notable differences in the incidence of childhood leukemia were observed among 4 racial/ethnic groups in California. Factors that may contribute to these differences include differential exposure to carcinogens and/or genetic susceptibility. Cancer 2016. © 2016 American Cancer Society. Cancer 2016;122:2867–2875. © 2016 American Cancer Society
Open AccessChildhood leukemia incidence in California: High and rising in the Hispanic population
BACKGROUND: High rates of childhood leukemia incidence have been reported in Latin America and among Hispanic children in the United States. California's large Hispanic population affords an important opportunity to perform a detailed analysis of the leukemia burden among Hispanic children.METHODS: Leukemias diagnosed among non‐Hispanic white (NHW), Hispanic, African American (AA), and Asian/Pacific Islander (API) children aged birth to 19 years between January 1, 1990 and December 31, 2012 were obtained from the California Cancer Registry (11,084 cases). Age‐adjusted incidence rates, standardized rate ratios (SRRs), and secular trends in incidence (annual percent change [APC]) were analyzed by subtype, race/ethnicity, sex, and age.RESULTS: Compared with NHW children, the incidence of acute lymphoblastic leukemia (ALL) was higher among Hispanic (SRR, 1.32) and lower among AA (SRR, 0.55) and API (SRR, 0.91) children. From 1990 to 2012, the incidence of ALL increased overall (APC, 1.1%) and among males (APC, 1.0%), females (APC, 1.3%), Hispanics (APC, 1.1%), AAs (APC, 1.9%), AA males (APC, 2.8%), API males (APC, 1.9%), and Hispanic females (APC, 1.5%). The incidence of ALL increased among Hispanic males aged 15 to 19 years (APC, 2.5%) and Hispanic females aged birth to 4 years and 15 to 19 years (APCs of 2.2% and 1.9%, respectively). The incidence of acute myeloid leukemia did not appear to differ among racial/ethnic groups. From 1990 to 2012, the overall incidence of acute myeloid leukemia remained stable but increased among Hispanics (APC, 1.2%), females (APC, 1.0%), Hispanic females (APC, 2.3%), and Hispanic females aged 15 to 19 years (APC, 3.4%).CONCLUSIONS: Notable differences in the incidence of childhood leukemia were observed among 4 racial/ethnic groups in California. Factors that may contribute to these differences include differential exposure to carcinogens and/or genetic susceptibility. Cancer 2016. © 2016 American Cancer Society. Cancer 2016;122:2867–2875. © 2016 American Cancer Society